Terms: = Liver cancer AND ERBB3, c-erbB3, 2065, P21860, p180-ErbB3, c-erbB-3, ErbB-3, MDA-BF-1, HER3, p85-sErbB3, MGC88033, p45-sErbB3, ENSG00000065361, erbB3-S
95 results:
1. Circ_0098823 binding with IGF2BP3 regulates DNM1L stability to promote metastasis of hepatocellular carcinoma via mitochondrial fission.
Yan J; Wang X; Fan Z; Xu Y; Zhang Y; Liu Y; Guo L; Liu D
Apoptosis; 2024 Jun; 29(5-6):709-725. PubMed ID: 38459420
[TBL] [Abstract] [Full Text] [Related]
2. Prognostic and predictive biomarkers for anti-EGFR monoclonal antibody therapy in RAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis.
Lu X; Li Y; Li Y; Zhang X; Shi J; Feng H; Yu Z; Gao Y
BMC Cancer; 2023 Nov; 23(1):1117. PubMed ID: 37974093
[TBL] [Abstract] [Full Text] [Related]
3. her3- A key survival pathway and an emerging therapeutic target in metastatic colorectal cancer and pancreatic ductal adenocarcinoma.
Desai O; Wang R
Oncotarget; 2023 May; 14():439-443. PubMed ID: 37163206
[TBL] [Abstract] [Full Text] [Related]
4. Combined Hepatocellular-Cholangiocarcinoma With Ductal Plate Malformation Pattern: A Case Report With Molecular Analysis.
Moon WS; Song JS; Yu HC; Kim KM; Ahn AR
Int J Surg Pathol; 2024 Feb; 32(1):160-164. PubMed ID: 37128663
[TBL] [Abstract] [Full Text] [Related]
5. Pan-cancer gene expression analysis of tissue microarray using EdgeSeq oncology biomarker panel and a cross-comparison with HER2 and her3 immunohistochemical analysis.
Inaki K; Shibutani T; Maeda N; Eppenberger-Castori S; Nicolet S; Kaneda Y; Koyama K; Qiu Y; Wakita K; Murakami M
PLoS One; 2022; 17(9):e0274140. PubMed ID: 36137139
[TBL] [Abstract] [Full Text] [Related]
6. liver Endothelium Promotes her3-Mediated Cell Survival in Colorectal cancer with Wild-Type and Mutant KRAS.
Rathore M; Zhang W; Wright M; Bhattacharya R; Fan F; Vaziri-Gohar A; Winter J; Wang Z; Markowitz SD; Willis J; Ellis LM; Wang R
Mol Cancer Res; 2022 Jun; 20(6):996-1008. PubMed ID: 35276002
[TBL] [Abstract] [Full Text] [Related]
7. Elevated coffee consumption is associated with a lower risk of elevated liver fibrosis biomarkers in patients treated for chronic hepatitis B (ANRS CO22 Hepather cohort).
Barré T; Fontaine H; Ramier C; Di Beo V; Pol S; Carrieri P; Marcellin F; Cagnot C; Dorival C; Zucman-Rossi J; Zoulim F; Carrat F; Protopopescu C
Clin Nutr; 2022 Mar; 41(3):610-619. PubMed ID: 35124468
[TBL] [Abstract] [Full Text] [Related]
8. The Yin and Yang of ERBB4: Tumor Suppressor and Oncoprotein.
Lucas LM; Dwivedi V; Senfeld JI; Cullum RL; Mill CP; Piazza JT; Bryant IN; Cook LJ; Miller ST; Lott JH; Kelley CM; Knerr EL; Markham JA; Kaufmann DP; Jacobi MA; Shen J; Riese DJ
Pharmacol Rev; 2022 Jan; 74(1):18-47. PubMed ID: 34987087
[TBL] [Abstract] [Full Text] [Related]
9. Molecular insight into the affinity, specificity and cross-reactivity of systematic hepatocellular carcinoma RALT interaction profile with human receptor tyrosine kinases.
Lu G; Li X; Zhang J; Xu Q
Amino Acids; 2021 Nov; 53(11):1715-1728. PubMed ID: 34618235
[TBL] [Abstract] [Full Text] [Related]
10. UHRF2 promotes Hepatocellular Carcinoma Progression by Upregulating erbb3/Ras/Raf Signaling Pathway.
Sun J; Wu K; Chen S; Jiang S; Chen Y; Duan C
Int J Med Sci; 2021; 18(14):3097-3105. PubMed ID: 34400880
[TBL] [Abstract] [Full Text] [Related]
11. Upregulation of the ErbB family by EZH2 in hepatocellular carcinoma confers resistance to FGFR inhibitor.
Prawira A; Le TBU; Ho RZW; Huynh H
J Cancer Res Clin Oncol; 2021 Oct; 147(10):2955-2968. PubMed ID: 34156519
[TBL] [Abstract] [Full Text] [Related]
12. her3 PET Imaging Identifies Dynamic Changes in her3 in Response to HER2 Inhibition with Lapatinib.
Wehrenberg-Klee E; Sinevici N; Nesti S; Kalomeris T; Austin E; Larimer B; Mahmood U
Mol Imaging Biol; 2021 Dec; 23(6):930-940. PubMed ID: 34101105
[TBL] [Abstract] [Full Text] [Related]
13. A Phase I Study of Alpelisib in Combination with Trastuzumab and LJM716 in Patients with
Jhaveri K; Drago JZ; Shah PD; Wang R; Pareja F; Ratzon F; Iasonos A; Patil S; Rosen N; Fornier MN; Sklarin NT; Chandarlapaty S; Modi S
Clin Cancer Res; 2021 Jul; 27(14):3867-3875. PubMed ID: 33947692
[TBL] [Abstract] [Full Text] [Related]
14. Pan-ERBB kinase inhibition augments CDK4/6 inhibitor efficacy in oesophageal squamous cell carcinoma.
Zhou J; Wu Z; Zhang Z; Goss L; McFarland J; Nagaraja A; Xie Y; Gu S; Peng K; Zeng Y; Zhang X; Long H; Nakagawa H; Rustgi A; Diehl JA; Meyerson M; Wong KK; Bass A
Gut; 2022 Apr; 71(4):665-675. PubMed ID: 33789967
[TBL] [Abstract] [Full Text] [Related]
15. Ebp1 p48 promotes oncogenic properties in hepatocellular carcinoma through p38 MAPK/HIF1α activation and p53 downregulation.
Bao Y; Suvesh M; Li X; Bai X; Li H; Li X; Xu D; Liu L
Mol Carcinog; 2021 Apr; 60(4):252-264. PubMed ID: 33634940
[TBL] [Abstract] [Full Text] [Related]
16. EV20‑sss‑vc/MMAF, an HER‑3 targeting antibody‑drug conjugate displays antitumor activity in liver cancer.
D'Agostino D; Gentile R; Ponziani S; Di Vittorio G; Dituri F; Giannelli G; Rossi C; Marzullo L; Giansanti F; De Laurenzi V; Iacobelli S; Ippoliti R; Capone E; Sala G
Oncol Rep; 2021 Feb; 45(2):776-785. PubMed ID: 33416143
[TBL] [Abstract] [Full Text] [Related]
17. Systems analysis of protein signatures predicting cetuximab responses in KRAS, NRAS, BRAF and PIK3CA wild-type patient-derived xenograft models of metastatic colorectal cancer.
Lindner AU; Carberry S; Monsefi N; Barat A; Salvucci M; O'Byrne R; Zanella ER; Cremona M; Hennessy BT; Bertotti A; Trusolino L; Prehn JHM
Int J Cancer; 2020 Nov; 147(10):2891-2901. PubMed ID: 32700762
[TBL] [Abstract] [Full Text] [Related]
18. Regulation of the EGFR/ErbB signalling by clathrin in response to various ligands in hepatocellular carcinoma cell lines.
Liu Y; Calmel C; Desbois-Mouthon C; Sobczak-Thépot J; Karaiskou A; Praz F
J Cell Mol Med; 2020 Jul; 24(14):8091-8102. PubMed ID: 32515546
[TBL] [Abstract] [Full Text] [Related]
19. miR-296-5p suppresses stem cell potency of hepatocellular carcinoma cells via regulating Brg1/Sall4 axis.
Shi DM; Shi XL; Xing KL; Zhou HX; Lu LL; Wu WZ
Cell Signal; 2020 Aug; 72():109650. PubMed ID: 32320856
[TBL] [Abstract] [Full Text] [Related]
20. Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib.
Giannelli G; Santoro A; Kelley RK; Gane E; Paradis V; Cleverly A; Smith C; Estrem ST; Man M; Wang S; Lahn MM; Raymond E; Benhadji KA; Faivre S
PLoS One; 2020; 15(3):e0222259. PubMed ID: 32210440
[TBL] [Abstract] [Full Text] [Related]
[Next]
